AbbVie | ABBV - Cost Of Sales


AbbVie reported $4.29B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Abbott USD 5.94B 642M Jun/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eisai JPY 51.09B 926M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
J&J USD 8B 67M Jun/2026
Medtronic USD 3.8B 195M Mar/2026
Merck USD 3.14B 200M Jun/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Perrigo USD 708.9M 65.2M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
UCB EUR 1.07B 146M Dec/2025
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
United Therapeutics USD 99.5M 33.9M Jun/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026
Zoetis USD 704M 32M Jun/2026